Considering Treatment Goals Beyond Systemic Efficacy
As survival outcomes improve in mNSCLC, patients are spending more time on therapy1
When treating patients with ALK+ mNSCLC in the first-line, secondary treatment goals such as long-term tolerability and quality of life have become increasingly important for overall disease management.1-3
Which of these other considerations is a top priority for you?
National Comprehensive Cancer Network® (NCCN®): recommends brigatinib as a Category 1, preferred first-line treatment option for ALK+ metastatic NSCLC4,a,b,c
Learn how to get your patient started on ALUNBRIG® (brigatinib)
aWhen an ALK rearrangement is discovered prior to first-line systemic therapy.4
bThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
cSee the NCCN Guidelines® for detailed recommendations, including other preferred treatment options.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; CNS, central nervous system; mNSCLC, metastatic NSCLC; NSCLC, non-small cell lung cancer.